Patients and exposure
From 28 October 2019 through 3 November 2021, 986 patients in 20 countries worldwide were screened at 129 sites, and 790 were randomized 2:1 to receive nivolumab (526 patients) or placebo (264 patients) at 119 sites (Fig. 